Skip to content
About Us
Our Company
Our Team
Directors
Contact
Our Science
VAAST Platform
Mucosal Immunity
Platform Difference
Pipeline
COVID-19
Norovirus
Influenza
HPV
Publications
Investors
Careers
Vaxart Guiding Principles
Benefits
Open Positions
Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
June 26, 2026
Vaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting
June 16, 2026
Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
June 8, 2026
Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders
June 1, 2026
Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders
May 19, 2026
Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results
May 7, 2026
Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET
May 1, 2026
Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors
April 23, 2026
Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital
April 17, 2026
Vaxart Provides Business Update and Reports Full Year 2025 Financial Results
March 12, 2026
←
Previous Page
1
2
3
4
…
6
Next Page
→
